New York Professional Events List


24th International Conference on Vaccine Design, Production & Safety (pgr)


Date
May 21, 2018 - 09:00 AM - May 22, 05:00 PM
Organizer
Pulsus Group - NewYorkEventsList
Location
Fleming's Conference Hotel Wien26-28 Neubaugürtel1070 WienAustria,

Austria,
Austria,
US,
ZIP: Austria
Phone:

Description

Pulsus Group.invites all the participants from all over the world to attend “24th International Conference on Vaccine Design, Production & Safety” to be held on May 21-22, 2018, Vienna, Austria. Vaccine Design 2018 focuses on the theme “Deliberation on modern vaccine research and development focusing on vaccine design delivery and evaluation “which aims in gathering the eminent research communities catalyzing information exchange and networking between researchers and business entrepreneurs of diverse backgrounds fostering advancements in Vaccine Design research

PULSUS has acknowledged you as a world class expert capable of providing deep insight into the latest developments in your field. Basing on your eminence and expertise in the field, we are honored to invite as an Organizing Committee Member for Vaccine Design 2018 this will allow reflecting on the Vaccine Design, Production & Safety at 360 degrees, all-round by expanding the knowledge of everyone.

 

For More information regarding abstract submission, please contact Program Director
Vaccine Design 2018

Welcome Message

Pulsus Group invites all the participants from all over the world to attend “24th International Conference on Vaccine Design, Production & Safety” to be held on May 21-22, 2018, Vienna, Austria. Vaccine Design 2018 is based on the theme “Deliberation on modern vaccine research and development focusing on vaccine design, delivery and evaluation”. This includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

The aim of Vaccine Design 2018 is to bring together leading academic Scientists, Researchers, professors, Business delegates, talented student communities and research scholars to commerce and share their experiences and research conclusion about all aspects of Vaccine Design & Development and its safety.

Vaccine Design 2018 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers.

Why to attend???

Vaccine Design 2018 is intended to provide a notable opening to the experts in the field of Vaccine Research & Development & its Safety to discuss latest research and challenges in the arena. Vaccine Design 2018 is planned to provide a special podium for health-care professionals, researchers, Business delegates and students working in the arena to consciously, exchange visions and their understandings in front of a large intercontinental listeners. This Vaccine Design, Production & Safety conferences, Vaccine events and Vaccine meetings will help in interaction with different brains in Vaccine Research & Development, B2B construction between specialists and academicians. The companies dealing with Vaccine products and supplements can exhibit their products in the Vaccine exhibition and expo.


Target Audience:

Vaccinology/Immunology, Scientists
Vaccinology Researchers
Vaccinology Faculty
Medical Colleges Faculty, Students
Immunology Associations and Societies
Business Entrepreneurs
Vaccines Training Institutes
Software developing companies
Manufacturing Medical Devices Companies
Clinical Data Management Companies
Machinery Manufacturing Companies

Sessions/Tracks

Pulsus Group invites all the participants from all over the world to attend “24th International Conference on Vaccine Design, Production & Safety” to be held on May 21-22, 2018, Vienna, Austria.which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Track 1: Vaccines Research and Production Technology

Vaccines Research and Production Technology With the emergence and growth of new diseases, the need and demand for innovative vaccines continues to grow. But vaccine development is a complex, laborious, and expensive process. It involves a demand of multiple technologies, sufficient funds for clinical trials and manufacturing facilities, sophisticated scale-up processes, knowledge in navigating demanding regulatory environments in various regions, and managing vital safety monitoring.

Track 2: Vaccine Design & Development

Vaccines Design & Development have been used against infectious disease, so it is basically required a revolution in the approach to vaccine design and development. Particular vaccines are involved to act against specific diseases. For example polio vaccines are recommended for vaccination against polio virus. New technologies such as genomics, proteomics, functional genomics, and synthetic chemistry can be used for the rational identification of antigens, the synthesis of complex glycans, the generation of engineered carrier proteins, and much more that are needed in designing vaccines. Vaccine design and development services help to reduce the cost of failure and increase the chance of clinical success.

Track 3: Vaccine Production & Development

Vaccine development is an activity that focuses on a variety of technological initiatives and applied research, which enhance and promote improved systems and practices for vaccine safety. In the past year, the unprecedented Ebola disease outbreak galvanized research and industry response and as we continue to search for solutions, we must review the lessons learned in order to overcome the current challenges. Vaccine development is a long, complex process, often lasting 10-15 years and involving a combination of public and private involvement. The current system for developing, testing, and regulating vaccines developed during the 20th century as the groups involved standardized their procedures and regulations.

 

Track 4: Conjugate Vaccines

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Conjugate vaccines also have antigens or toxoids, often from the same bacteria, linked to the sugar molecules. Conjugate vaccines only use a small part of a bacterium linked to carrier protein. Conjugate vaccines are primarily used for the prevention of bacterial infections. Polysaccharide protein conjugate vaccines comprise of polysaccharides, generally from the surface coat of bacteria, linked to protein carriers. The advantages of the conjugate vaccines are their capacity to create immunological memory and to decrease asymptomatic carriage of the microbes, resulting in marked herd immunity. Conjugate vaccines can reduce complexity and increase coverage.

Track 5: Vaccine Development and Implementation

Vaccine Development is a complex and time-consuming process that differs from the development of conventional drugs. Vaccine clinical trials focus on demonstrating prevention of a disease which implies that a higher number of subjects will be required than for traditional drug trials. The researchers will test the candidate vaccine for the first time in humans in order to evaluate its safety, determine a safe dosage range, and identify vaccine-related side effects. Once a vaccine has been marketed, pharmacovigilance activities take place in order to carry on a strict safety supervision of the vaccines and detect, assess, understand, prevent and communicate any adverse events following Track 5: immunisation, or of any other vaccine- or immunisation-related issues.

Track 6: Vaccines for Immune Mediated Diseases

Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immune-modulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humeral response to vaccination in IMID patients has been demonstrated for Hepatitis B, Influenza and Pneumococcal vaccination.

 

Track 7: Public Health Effectiveness of Vaccine Implementation

Vaccines have helped to save millions and millions of lives. Infectious disease has always impacted humanity but with the development of vaccines the occurrence of infectious disease has been decreases. Vaccines made life more comfortable and hence various researches are still going on to cure various vaccine preventable diseases. Polio infection is on its way to eradication from all the countries and we will discuss more on the steps to eradicate polio. Polio eradication is a greatest achievement in field vaccine development. Public Health's Immunization Program aims to assist all in attaining optimal health through knowledge of and access to immunizations.

Track 8: Vaccines for infants, children, and adults

A vaccine is a biological preparation that provides active acquired immunity to a particular disease and dates it uses back from a long time. Infections are always better if prevented then trying to cure them at later stages and the best way to ensure we are protected is to ask our healthcare provider if our vaccinations are up to date. Proper timing of vaccination is another key point to be noted and we would discuss various vaccines available for infants, adolescents and adults along with their schedules and risks factors involved.

Track 9: Vaccines Storage and Handling

Immunizations help save lives, prevent serious illnesses, and are recognized as one of the most effective public health interventions available today. Vaccines immunology programs are among the most cost-effective ways to prevent disease. The success of these programs depends heavily upon the high immunization coverage of the target group and vaccine inventory management, including proper storage and handling of vaccines. This document is intended to assist all health care providers with how to properly store and handle provincially funded vaccines. Prior to storing vaccine, health care providers are required to understand and meet with the vaccine storage and handling requirements indicated in this document.

Track 10: Bacterial Vaccines

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes. Bacterial Vaccines is a preparation of killed or attenuated bacteria used as an active immunizing agent and a large number of deaths could be reduced by increased use of present vaccines and even more deaths can be prevented by the future use of new vaccines being developed. We would be glad to welcome and bring together the Global leaders in Immunology and relevant fields to present their research at this exclusive scientific program. Vaccine design 2018 Organizing Committee also invites Young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions.

Track 11: Vaccine Efficacy and Safety

Vaccines have significantly reduced the burden of infectious diseases. Recognized vaccine safety issues are commonly reported while reviews of vaccine adjuvants are few. Vaccines are developed in accordance with the highest standards of safety because vaccines must be safe for use by as many people as possible. Individuals respond differently to vaccines, and there is no way to absolutely guess the reaction of a specific individual to a particular vaccine. Immunization is the safest and most effective public health tool available for preventing disease and death. Efficacious vaccines protect individuals if administered before exposure.

Track 12: Vaccine Adjuvants

Vaccine Adjuvants is a part of a vaccine that helps to create a stronger immune response in the patient’s body. Some vaccines prepared from weakened or dead germs contain naturally occurring adjuvants and aid the body produce a strong protective immune response. With the advancement of new and less reactogenic vaccine antigens, additionally comes the requirement for more viable adjuvants that will encourage the acceptance of adaptive immune responses. Vaccines made with adjuvants ensure the body to produce an immune response to protect the patient from the germ he or she is being vaccinated against. Vaccine adjuvants improve the body's immune response and often allow for smaller amounts of an inactivated virus or bacteria to be used in a vaccine. Aluminium salts, such as aluminium hydroxide, aluminium phosphate, and aluminium potassium sulphate have been used safely as adjuvant in vaccines.

Track 13: Plant derived Vaccines

Plant-determined immunizations show another option to traditional vaccine by encouraging sheltered and viable oral delivery through utilization of eatable plant tissue. Numerous infectious diseases enter the body through mucosal surfaces, for example, the gut, and accordingly, vaccines expressed in the form of edible plant tissues offer a select preferred advantage. The plant tissues can secure the antigen as it goes through the digestive tract. Vaccines derived from transgenic plants are convenient and inexpensive source for various bacterial, viral, protozoan and autoimmune diseases with lower capital costs.

Track 14:Vaccines against Drugs

Drug addiction is a serious problem worldwide. One therapy being investigated is vaccines against drugs of abuse. The antibodies elicited against the drug can take up the drug and prevent it from reaching the reward centres in the brain. Few such vaccines have entered clinical trials, but research is going on apace. Many studies are very promising and more clinical trials should be coming out in the near future.

 

Track 15: Vaccines and Vaccination

Vaccines and Vaccination is generally considered to be the most effective method of preventing infectious diseases. All vaccinations work by presenting a foreign antigen to the immune system in order to evoke an immune response. The purpose of every vaccination is to present a particular antigen or set of antigens to the immune system in order to evoke a relevant immune response. Vaccines help make you immune to serious diseases without getting sick first. Without a vaccine, you must actually get a disease in order to become immune to the germ that causes it. Vaccines work best when they are given at certain ages. Proper timing of vaccination is key point to be noted and we would discuss various vaccines available for infants, adolescents and adults along with their schedules and risks factors involved.

Track 16: Vaccine Safety, Surveillance and Evaluation

Vaccine is a biological product that improves and develops immunity to a given disease. A vaccine comprises a disease-causing microorganism, or portion of it, and is often made from either live-attenuated or inactivated (killed) forms of the microbe, its toxin or one of its surface proteins. Vaccines used in national immunizationprogrammes are extremely safe and effective. Public health are required know about both protection from infectious diseases and protection from chronic health conditions. Public alertness regarding vaccine safety has increased through awareness and increased access to information through the internet. Various vaccination programmes are also organised to have immunized from vaccine preventable diseases. Vaccines are normally programmed early in life when infections and other illnesses are new.

Track 17: Vaccine Industries

Vaccine Industries is the fastest–growing part of business all over the world. A great deal of medical research into vaccines is undertaken by scientists working directly or indirectly for the pharmaceutical companies. New technologies and research works are still on process for vaccine design and development for the new infectious diseases. Vaccines should be safe and more effective against the particular diseases.

Track 18: Immunization Safety and Vaccination Schedule

First we are assured that, thanks to vaccines, some diseases are almost gone from the U.S. But we are also warned to immunize our children, ourselves as adults, and the elderly. Unless we can "stop the leak" (eliminate the disease), it is important to keep immunizing. Even if there are only a few cases of disease today, if we take away the protection given by vaccination, more and more people will become infected and will spread disease to others as well the vaccination schedule is an important key for eradication a diseases. Soon we will undo the progress we have made over the years.

Track 19: DNA Vaccines:

DNA vaccination is a technique for protecting an animal against disease by injecting it with genetically engineered DNA so cells directly produce an antigen, resulting in a protective immunological response.

Vaccination consists of stimulating the immune system with an infectious agent, or components of an infectious agent, modified in such a manner that no harm or disease is caused, but ensuring that when the host is confronted with that infectious agent, the immune system can adequately neutralize it before it causes any ill effect. For over a hundred years vaccination has been effected by one of two approaches: either introducing specific antigens against which the immune system reacts directly; or introducing live attenuated infectious agents that replicate within the host without causing disease synthesize the antigens that subsequently prime the immune system.

The field of DNA vaccination is developing rapidly. Vaccines currently being developed use not only DNA, but also include adjuncts that assist DNA to enter cells, target it towards specific cells, or that may act as adjuvants in stimulating or directing the immune response. Ultimately, the distinction between a sophisticated DNA vaccine and a simple viral vector may not be clear. Many aspects of the immune response generated by DNA vaccines are not understood. However, this has not impeded significant progress towards the use of this type of vaccine in humans, and clinical trials have begun.

Track 20: Current Research & Future Challenges

Vaccine development remains challenging because of the highly sophisticated evasion mechanisms of pathogens for which vaccines are not yet available. Recent years have witnessed both successes and failures of novel vaccine design and the strength of iterative approaches is increasingly appreciated. These combine discovery of novel antigens, adjuvants and vectors in the preclinical stage with computational analyses of clinical data to accelerate vaccine design. Reverse and structural vaccinology have revealed novel antigen candidates and molecular immunology has led to the formulation of promising adjuvants. Gene expression profiles and immune parameters in patients, vaccines and healthy controls have formed the basis for bio-signatures that will provide guidelines for future vaccine design.

 

Track 21: HPV Vaccines:

Human Papillomavirus (HPV) vaccine is an inactivated (not live) vaccine which protects against four major types of HPV.

These include two types that cause about 70% of cervical cancer and two types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer. Protection from HPV vaccine is expected to be long-lasting. But vaccinated women still need cervical cancer screening because the vaccine does not protect against all HPV types that cause cervical cancer.

Routine HPV Vaccination

  • HPV vaccine is routinely recommended for girls 11 and 12 years of age
  • The HPV4 vaccine (the type recommended for prevention of genital warts in girls) may also be given in three doses to boys aged 9 to 26.

It is important for girls to get HPV vaccine before their first sexual contact -- because they have not been exposed to HPV. For these girls, the vaccine can prevent almost 100% of disease caused by the four types of HPV targeted by the vaccine. However, if a girl or woman is already infected with a type of HPV, the vaccine will not prevent disease from that type. The vaccine is also recommended for girls and women 13 through 26 years of age who did not receive it when they were younger.

Track 22: Plant-based vaccines:

Plant-based vaccines are recombinant protein subunit vaccines. Ideally, the choice of plant species used to produce the selected antigen should allow for oral drug delivery in the form of an edible vaccine. To date, the most advanced human vaccine projects have successfully completed phase I clinical trials, and animal vaccine projects have given promising data in early phase trials targeting specific animal species.

The plant-based vaccine production method works by isolating a specific antigen protein, one that triggers a human immune response from the targeted virus. A gene from the protein is transferred to bacteria, which are then used to “infect” plant cells. The plants then start producing the exact protein that will be used for vaccinations. The flexibility of the plant expressed vaccine system, combined with its low cost and ability to massively scale may provide vaccine protection not only to citizens of the United States, but to many parts of the world that cannot currently afford vaccines. Other uses of plant expressed vaccines including the successful creation of edible bananas that protect against the Norwalk virus.

Market Analysis

Vaccine Design 2018

Theme: “Deliberation on modern vaccine research and development focusing on vaccine design, delivery and evaluation”.

Summary

Traditionally Vaccines have been used to eradicate infectious diseases, which started with Small Pox. Apparently In the last few years there is great advancement towards vaccine design and its development. In the Era of Molecular biology the innovative technologies such as genomics, proteomics, and functional genomics are used for the rational identification of antigens, generation of engineered carrier proteins and much more. The research in this area has always been more exciting with ever new outbreak the nature throws from influenza to Zika.

Vaccine Design 2018 is an ideal forum for the researchers and Healthcare professionals to discuss on the current advancements in Vaccine design towards the most precise way of immunization.

 

For more details please visit- http://vaccinedesign.cmesociety.com/

Importance and Scope

“24th International Conference on Vaccine Design, Production & Safety” to be held on May 21-22, 2018, Vienna, Austria hosted by Pulsus Group, the conference will explore the advances in Vaccine Research, Development & Design. This conference could be an exceptional event that brings along a novel and International mixture of giant and medium cognizance on Vaccines and its safety, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world.

Conference Highlights:

 
  • Vaccines Research and Production Technology
  • Vaccine Design & Development
  • Conjugate vaccines
  • Vaccine Development and Implementation
  • Public Health Effectiveness of Vaccine Implementation
  • Vaccines for infants, children, and adult
  • Vaccines Storage and Handling
  • Bacterial vaccines
  • Vaccine Efficacy and Safety
  • Vaccine adjuvants
  • Plant derived vaccines
  • Vaccines and vaccination
  • Vaccine Safety, Surveillance and Evaluation
  • Vaccine Industries
  • Immunization Safety and Vaccination Schedule
 

Vaccine Global Market:

The vaccines market has been drastically growing, the in the last decade where there is a huge leap from 6 billion USD in 2000 to 33 billion USD in 2014 it is expected to reach 48.03 Billion by 2021(Fig2). Going on the basis of Molecular technology, the vaccines market is projected to a have drastic growth in next few years. The market share is dominated by High Income Countries with 61%, upper and Lower middle income countries with 23% and 8% respectively and Low income countries with 6 %( Fig.1). There are lots of other Emerging manufacturers from India, China, Brazil who are playing vital role and contributing to the market share (Fig.3). The government support and other funding bodies are into vaccine development and there is indeed progress in this business &investments will drive the growth of this market segment.

 

 

 

 

Major Vaccine Manufacturers

 

 

Industries Associated with Vaccines

 

Vienna

Austria

Worldwide

• Novartis

• PraxisUnico

• DiscoveRx

• Parexel

• The Binding Site

• The Jenner Institute

  • Astex
  • AstraZeneca (Med Immune)
  • BTG
  • Cyclacel
  • Dechra Pharmaceuticals
  • GE Healthcare
  • Genus
  • GlaxoSmithKline
  • Hikma Pharmaceuticals
  • Indivior
  • MacFarlan Smith
  • Norbrook Group
  • Oxford BioMedica
  • Pfizer UK

 

  • Lipotek Acton - ACT, Australia
  • Admedus East Perth, WA, Australia
  • Gamma Vaccines Manuka, ACT, Australia
  • Sementis Melbourne, VIC, Australia
  • bioCSL (CSL) Parkville, VIC, Australia
  • Vaxxas Nanopatch Sydney, Australia
  • AFFiRiS Vienna, Austria
  • Sinovac Biotech - Beijing, China
  • Vaxon Biotech - Paris, France
  • VitamFero - Tours, France
  • GlaxoSmithKline - Madrid, Spain
  • GlaxoSmithKline - Gloucestershire, UK
  • Antitope (Abzen) - Cambridge, UK

Universities Associated with Vaccine Research

Vienna

Austria

Worldwide

  • University of Vienna
  • University of Alabama
  • Vienna City University
  • Medical University of Vienna

 

 

  • Danube Private University
  • St George's University of London
  • Benedict XVI Philosophical-Theological University,
  • University College Austria
  • Heriot-Watt University, Edinburgh Campus
  • Medical University Innsbruck
  • Kingston University London

 

  • Harvard University
  • University of Oxford
  • University of Cambridge
  • Johns Hopkins University
  • Stanford University
  • University of California, San Francisco
  • University of California, Los Angeles (UCLA)
  • Yale University
  • Karolinska Institute
  • ULC London
  • Imperial College London
  • University of Pennsylvania
  • Duke University
  • University of Toronto
  • Columbia University
  • The University of Sydney
  • The University of Melbourne
  • University of Washington

Vaccine Production:

 

 

Funding for Vaccine Design Research:

Austria In 2007, the Medical Research Council reviewed its vaccine research portfolio and concluded that it needed to strengthen its translational research by accelerating basic vaccine research into product development and clinical practice and using vaccine research to inform immunization policies. Five projects have received funding, including a study to monitor the effectiveness of HPV vaccines in teenage girls. There are some academic centers which focus on vaccine research. Some, such as the Jenner Institute in Oxford, specialize in researching novel candidate vaccines. The limiting step for such institutes is the expense of producing batches of novel vaccines and testing them in clinical trials. In 2005, in an effort to encourage UK based pharmaceutical manufacture (including vaccines) the government invested £30m in establishing a National Bio-manufacturing Centre. This facility can produce a wide variety of biopharmaceuticals (including vaccines) under contract from the private sector and academia

Global Funding Bodies:

  • United Nations Children’s Fund (UNICEF)
  • Centre for Disease Control and Prevention (CDC)
  • Bill and Melinda Gates Foundation
  • American Academy of Pediatrics (AAP)
  • Vaccine Foundation (V Foundation)
  • Rockefeller Foundation (RF)
  • National Institute of Health(NIH)
  • Children’s Vaccine Initiative (CVI)
  • Global Alliance for Vaccines and Immunization (GAVI)

Target Audience:

The conference discusses the latest research outcomes and technological advancements in regards with Vaccine development matching with latest trend; it as well brings together leading Health care professionals Immunologists, Physicians, Research Scholars, Students along with Industries. This forum is for professionals to exchange and share their views on critical aspects of Vaccines research. Vaccine Design 2018 will give you the opportunity to meet the main experts around the world, present your own discovery or work, and interact with your peers. Furthermore, the stimulating scientific program will provide you to enrich professionally and socially, providing the chance to keep in touch with other participants for establishing any new future collaborations.’

Pulsus Group invites participants from all over the world to attend “24th International Conference on Vaccine Design, Production & Safety” to be held on May 21-22, 2018, Vienna, Austria. Vaccine Design 2018 is based on the theme “Deliberation on modern vaccine research and development focusing on vaccine design, delivery and evaluation”. This includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

 

 

 

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for: 
- Discounts for multiple participants.
- Require a price quotation.
- Require to pay by wire transfer or PayPal
- Invitation letter for visa applications

NO REFUNDS ALLOWED ON REGISTRATIONS 
-----------------------------------------------------------------
This Event is Brought to You by: 
Pulsus Group - NewYorkEventsList
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com

MYL171010CEV


 

Event Categories
BUSINESS & MANAGEMENT CONFERENCES
,
Technology
Keywords: fun, analysis, access , analyses, applications, arts, audience, biology , business , class




Comments








Events Calendar

SunMonTueWedThuFriSat
29 30 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2

Event Location

Newsletters

Subscribe
VIP Life Time Subscription to our Newsletters!
$399.99
$299.99

Forbes Women's Summit 2018
Disrupt SF 2018 - Brought to you by Techcrunch
U.S. Naval Institute Annual Meeting 2018
Breast Cancer Research Foundation
Children’s Health Fund
The World Energy Engineering Congress (WEEC)
                            Oct. 17-19, 2018
                            Charlotte, NC